The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
Liangtao Ye(Sun Yat-sen University), Enrico N. De Toni(LMU Klinikum)
Cited by 60
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
|Liver Cancer|2023|44